Home Cart 0 Sign in  

[ CAS No. 593-71-5 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 593-71-5
Chemical Structure| 593-71-5
Structure of 593-71-5 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 593-71-5 ]

Related Doc. of [ 593-71-5 ]

Alternatived Products of [ 593-71-5 ]

Product Details of [ 593-71-5 ]

CAS No. :593-71-5 MDL No. :MFCD00001078
Formula : CH2ClI Boiling Point : -
Linear Structure Formula :- InChI Key :PJGJQVRXEUVAFT-UHFFFAOYSA-N
M.W : 176.38 Pubchem ID :11644
Synonyms :

Calculated chemistry of [ 593-71-5 ]

Physicochemical Properties

Num. heavy atoms : 3
Num. arom. heavy atoms : 0
Fraction Csp3 : 1.0
Num. rotatable bonds : 0
Num. H-bond acceptors : 0.0
Num. H-bond donors : 0.0
Molar Refractivity : 24.68
TPSA : 0.0 Ų

Pharmacokinetics

GI absorption : Low
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.27 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.4
Log Po/w (XLOGP3) : 1.56
Log Po/w (WLOGP) : 1.62
Log Po/w (MLOGP) : 1.82
Log Po/w (SILICOS-IT) : 2.02
Consensus Log Po/w : 1.68

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 3.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -1.92
Solubility : 2.14 mg/ml ; 0.0121 mol/l
Class : Very soluble
Log S (Ali) : -1.17
Solubility : 11.9 mg/ml ; 0.0676 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -1.85
Solubility : 2.5 mg/ml ; 0.0142 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 2.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 3.28

Safety of [ 593-71-5 ]

Signal Word:Danger Class:6.1
Precautionary Statements:P261-P264-P270-P271-P280-P301+P310+P330-P302+P352-P304+P340+P312-P305+P351+P338-P332+P313-P337+P313-P403+P233-P405-P501 UN#:2810
Hazard Statements:H301-H315-H319-H335 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 593-71-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 593-71-5 ]
  • Downstream synthetic route of [ 593-71-5 ]

[ 593-71-5 ] Synthesis Path-Upstream   1~11

  • 1
  • [ 593-71-5 ]
  • [ 28556-81-2 ]
  • [ 1131-01-7 ]
YieldReaction ConditionsOperation in experiment
97% With methyllithium; lithium bromide In diethyl ether at -78℃; for 0.5 h; General procedure: To a cooled (–78°C) solution of isocyanate (1.0 equiv) in dry Et2O (1 M concentration) was added the dihalomethane derivative (1.5 equiv). After 2 min, an ethereal solution of 1.5 M MeLi–LiBr (1.25equiv) was added dropwise over 5 min. The resulting solution was stirred for the appropriate time (see Table 1 and Scheme 2) at that temperature. Sat. aq NH4Cl was added (2 mL/mmol substrate) and the cooling bath was removed, the mixture was stirred till it reached r.t., and then it was extracted with additional Et2O (2 × 5 mL) and washed with water (5 mL) and brine (10 mL). The organic phase was dried (anhyd Na2SO4), filtered, and the solvent removed under reduced pressure to give pure samples of haloacetamides.
Reference: [1] Chemical Communications, 2013, vol. 49, # 75, p. 8383 - 8385
[2] Synthesis (Germany), 2014, vol. 46, # 21, p. 2897 - 2909
  • 2
  • [ 74-85-1 ]
  • [ 593-71-5 ]
  • [ 6940-76-7 ]
Reference: [1] Journal of the American Chemical Society, 1950, vol. 72, p. 2213
  • 3
  • [ 593-71-5 ]
  • [ 1124-14-7 ]
Reference: [1] Patent: EP1364957, 2003, A1, . Location in patent: Page/Page column 23
  • 4
  • [ 593-71-5 ]
  • [ 4747-72-2 ]
  • [ 19047-31-5 ]
YieldReaction ConditionsOperation in experiment
95% With methyllithium; lithium bromide In diethyl ether at -78℃; for 1 h; General procedure: To a cooled (–78°C) solution of isocyanate (1.0 equiv) in dry Et2O (1 M concentration) was added the dihalomethane derivative (1.5 equiv). After 2 min, an ethereal solution of 1.5 M MeLi–LiBr (1.25equiv) was added dropwise over 5 min. The resulting solution was stirred for the appropriate time (see Table 1 and Scheme 2) at that temperature. Sat. aq NH4Cl was added (2 mL/mmol substrate) and the cooling bath was removed, the mixture was stirred till it reached r.t., and then it was extracted with additional Et2O (2 × 5 mL) and washed with water (5 mL) and brine (10 mL). The organic phase was dried (anhyd Na2SO4), filtered, and the solvent removed under reduced pressure to give pure samples of haloacetamides.
Reference: [1] Chemical Communications, 2013, vol. 49, # 75, p. 8383 - 8385
[2] Synthesis (Germany), 2014, vol. 46, # 21, p. 2897 - 2909
  • 5
  • [ 76-09-5 ]
  • [ 5419-55-6 ]
  • [ 593-71-5 ]
  • [ 83622-42-8 ]
YieldReaction ConditionsOperation in experiment
81%
Stage #1: With n-butyllithium In tetrahydrofuran; hexane at -78 - 20℃; for 2.83333 h;
Stage #2: With hydrogenchloride In tetrahydrofuran; hexane; ethyl acetate at 0℃;
Stage #3: at 0 - 20℃; for 0.666667 h;
(Production Example 1)
Synthesis of 2-(chloromethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
To the mixture of triisopropyl borate (15 ml, 65 mmol), chloroiodomethane (13 g, 72 mmol), and tetrahydrofuran (78 ml), n-butyllithium (a 1.6 M n-hexane solution, 41 ml, 65 mmol) was added dropwise at -78°C (an outer temperature) over 20 minutes, and then the obtained mixture was stirred at room temperature for 2.5 hours.
The reaction mixture was cooled to 0°C (an outer temperature), and a 4 N hydrochloric acid-ethyl acetate solution was added dropwise thereto at the same temperature until the reaction mixture became neutral.
At the same temperature, pinacol (7.7 g, 65 mmol) was added to the reaction mixture, and then the reaction mixture was stirred at room temperature for 40 minutes.
The solvents were evaporated under reduced pressure, and then the obtained residue was distilled under reduced pressure (63-70°C, 11 mmHg), thereby obtaining the entitled compound (9.2 g, 52 mmol, 81percent).
1H-NMR Spectrum (CDCl3) δ(ppm): 1.30(12H, s), 2.97(2H, s)
Reference: [1] Patent: EP2062901, 2009, A1, . Location in patent: Page/Page column 12
[2] Chemical Biology and Drug Design, 2011, vol. 78, # 5, p. 757 - 763
  • 6
  • [ 593-71-5 ]
  • [ 61676-62-8 ]
  • [ 83622-42-8 ]
YieldReaction ConditionsOperation in experiment
46%
Stage #1: With n-butyllithium In tetrahydrofuran at -78℃; for 0.5 h;
Stage #2: With chloro-trimethyl-silane In tetrahydrofuran at 20℃; for 24.17 h;
To a stirred solution of 2-isopropoxy-4,4,5,5-tetramethyl-1 ,3,2-dioxaborolane (1 1 .0 mL, 53.75 mmol) and chloroiodomethane (4.3 mL, 59.12 mmol) in anhydrous THF (100 mL), cooled to -78 °C, was added cold n-butyllithium solution (23.94 mL, 59.12 mmol) dropwise. After stirring for 30 min at this temperature, chlorotrimethylsilane (8.2 mL, 64.50 mmol) was added dropwise. After stiring for 10 min, the reaction mixture was allowed to return to room temperature and stirred for 24 h. Water (80 mL) was added and the mixture extracted with Ε∑0 (2 x 80 mL). The organic extracts were combined, washed with water (2 x 80 mL), dried over MgS04 and concentrated in vacuo. The crude product was purified by flash column chromatography on silica gel (Heptane/EtOAc 99:1 to 95:5).to yield 2-(chloromethyl)-4, 4, 5, 5-tetramethyl-1 ,3,2-dioxaborolane (4.35 g, 24.65 mmol, 46percent yield) as a colourless oil. NMR (400 MHz, DMSO-cfe, δ): 2.99 (s, 2H), 1 .32 (s, 12H).
Reference: [1] Journal of the American Chemical Society, 2012, vol. 134, # 42, p. 17470 - 17473
[2] Angewandte Chemie, International Edition, 2009, vol. 48, # 34, p. 6317 - 6319[3] Angewandte Chemie, 2009, vol. 121, # 34, p. 6435 - 6437
[4] Patent: WO2017/46604, 2017, A1, . Location in patent: Paragraph 00339; 00346
  • 7
  • [ 76-09-5 ]
  • [ 593-71-5 ]
  • [ 83622-42-8 ]
YieldReaction ConditionsOperation in experiment
81%
Stage #1: With n-butyllithium; Triisopropyl borate In tetrahydrofuran; hexane at -78 - 20℃; for 2.83 h;
Stage #2: With hydrogenchloride In tetrahydrofuran; hexane; ethyl acetate at 0℃;
Stage #3: at 0 - 20℃; for 0.666667 h;
To a mixture of triisopropyl borate (15 ml, 65 mmol), chloroiodomethane (13 g, 72 mmol) and tetrahydrofuran (78 ml) was added dropwise n-buthyllithium (1.6M n-hexane solution, 41 ml, 65 mmol) at -78°C (external temperature) over 20 minutes. Then, the mixture was stirred at room temperature for 2.5 hours. After the reaction mixture was cooled at 0°C (external temperature), to the mixture was added dropwise a 4N hydrochloric acid-ethyl acetate solution in order to neutralize at the same temperature. To the reaction mixture was added pinacol (7.7 g, 65 mmol) at the same temperature, and then, the reaction mixture was stirred at room temperature for 40 minutes. After the solvent was distilled off under reduced pressure, the resulting residue was distilled under reduced pressure (63-70°C, 11 mmHg) to obtain the title compound (9.2 g, 52 mmol, 81percent). 1H-NMR Spectrum (CDCl3) δ (ppm): 1.30 (12H, s) , 2.97(2H, s).
Reference: [1] Patent: EP1867650, 2007, A1, . Location in patent: Page/Page column 41
  • 8
  • [ 593-71-5 ]
  • [ 82034-46-6 ]
YieldReaction ConditionsOperation in experiment
89%
Stage #1: With sodium ethanolate In N,N,N,N,N,N-hexamethylphosphoric triamide at 20℃; for 24 h; Large scale
Stage #2: at 20℃; for 2 h; Large scale
To 50L reactor, add 1.9 kg intermediate 4, hexamethylphosphoric acid triamide 19L, sodium ethoxide 0.26 kg. React under the condition of room temperature for 24 hours. Add chloroiodomethane 1.4 kg. Stir for 2 hours. The reaction liquid quickly add 570L in water, separate out a large amount of yellow solid, filtering. The filter cake is added to the chloroform 5.7L dissolved, for sequentially 0.3M sodium thiosulfate solution 1.9L, 0 . 4M sodium bicarbonate solution, 1.9L saturated salt water 1.9L washing liquid, anhydrous sodium sulfate drying, decolorized with active carbon. Filtered, concentrated under reduced pressure to dryness; anhydrous ethanol is added 13.3L, heating to reflux, the solid is completely dissolved, gradually cooling crystallization, filtration. 40 °C blast drying, to obtain white solid 1.6 kg, yield 89percent.
Reference: [1] Patent: CN106554383, 2017, A, . Location in patent: Paragraph 0025; 0031; 0032
  • 9
  • [ 593-71-5 ]
  • [ 127132-32-5 ]
  • [ 152438-62-5 ]
YieldReaction ConditionsOperation in experiment
80% at -78℃; for 1 h; LDA (169 mL, 163 mmol) was added dropwise at 78 °C through a cannula to a mixture of iodochloromethane (9.45 mL, 130 mmol) and ethyl N-[(1,1-dimethylethyl)oxy]carbonyl}-O-(phenylmethyl)-L-tyrosinate (prepared as described in J. Med. Chem. 1990, 33, 1620) also at 78 °C. The resulting dark solution was stirred for one hour at 78 °C, then 50 mL of a 1:1 acetic acid:tetrahydrofuran solution was added slowly and the reaction was warmed to ambient temperature, poured onto a mixture of ice water and ethyl acetate, and the aqueous solution was extracted with ethyl acetate, the organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The brown solid was suspended in cold ether and filtered to give the title compound (3.17 g). The filtrate was concentrated under reduced pressure to give an additional 7.4 g of slightly impure title compound (10.57 g, 80percent yield). 1H NMR (400 MHz, CDCl3) δ 1.40 (s, 9H), 2.80-3.21 (m,2H), 3.87-4.25 (m, 2H), 4.42-4.72 (m, 1H), 5.03 (s, 2H), 6.81-7.17(m, 4H), 7.29-7.57 (m, 5H); LC/MS (m/z) ES+=427 (M + 23).
Reference: [1] Tetrahedron Letters, 1997, vol. 38, # 18, p. 3175 - 3178
[2] European Journal of Medicinal Chemistry, 2013, vol. 63, p. 202 - 212
[3] Bioorganic and Medicinal Chemistry Letters, 2005, vol. 15, # 15, p. 3496 - 3500
  • 10
  • [ 50651-75-7 ]
  • [ 593-71-5 ]
  • [ 258516-84-6 ]
Reference: [1] Patent: US2015/111858, 2015, A1, . Location in patent: Paragraph 0069
[2] Patent: WO2016/77346, 2016, A1, . Location in patent: Paragraph 0101
  • 11
  • [ 593-71-5 ]
  • [ 90084-26-7 ]
  • [ 84110-34-9 ]
Reference: [1] Organometallics, [2] Organometallics, 1985, vol. 4, p. 1687 - 1689
Same Skeleton Products
Historical Records